<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37349744</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>26</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1478-6362</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>22</Day></PubDate></JournalIssue><Title>Arthritis research &amp; therapy</Title><ISOAbbreviation>Arthritis Res Ther</ISOAbbreviation></Journal><ArticleTitle>Low-density granulocytes are related to shorter pregnancy duration but not to interferon alpha protein blood levels in systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>107</StartPage><MedlinePgn>107</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">107</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13075-023-03092-w</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">An increased risk of pregnancy complications is seen in women with systemic lupus erythematosus (SLE), but the specific immunopathological drivers are still unclear. Hallmarks of SLE are granulocyte activation, type I interferon (IFN) overproduction, and autoantibodies. Here we examined whether low-density granulocytes (LDG) and granulocyte activation increase during pregnancy, and related the results to IFN&#x3b1; protein levels, autoantibody profile, and gestational age at birth.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Repeated blood samples were collected during pregnancy in trimesters one, two, and three from 69 women with SLE and 27 healthy pregnant women (HC). Nineteen of the SLE women were also sampled late postpartum. LDG proportions and granulocyte activation (CD62L shedding) were measured by flow cytometry. Plasma IFN&#x3b1; protein concentrations were quantified by single molecule array (Simoa) immune assay. Clinical data were obtained from medical records.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Women with SLE had higher LDG proportions and increased IFN&#x3b1; protein levels compared to HC throughout pregnancy, but neither LDG fractions nor IFN&#x3b1; levels differed during pregnancy compared to postpartum in SLE. Granulocyte activation status was higher in SLE relative to HC pregnancies, and it was increased during pregnancy compared to after pregnancy in SLE. Higher LDG proportions in SLE were associated with antiphospholipid positivity but not to IFN&#x3b1; protein levels. Finally, higher LDG proportions in trimester three correlated independently with lower gestational age at birth in SLE.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our results suggest that SLE pregnancy results in increased peripheral granulocyte priming, and that higher LDG proportions late in pregnancy are related to shorter pregnancy duration but not to IFN&#x3b1; blood levels in SLE.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Torell</LastName><ForeName>Agnes</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Guldhedsgatan 10A, Gothenburg, 405 30, Sweden. agnes.torell.bjorkman@gu.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stockfelt</LastName><ForeName>Marit</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Guldhedsgatan 10A, Gothenburg, 405 30, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rheumatology, Sahlgrenska University Hospital, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larsson</LastName><ForeName>Gunilla</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Guldhedsgatan 10A, Gothenburg, 405 30, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Winsconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leonard</LastName><ForeName>Dag</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences, Rheumatology, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>R&#xf6;nnblom</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences, Rheumatology, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saleh</LastName><ForeName>Muna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Inflammation and Infection, Department of Biomedical and Clinical Sciences, Link&#xf6;ping University, Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sj&#xf6;wall</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Inflammation and Infection, Department of Biomedical and Clinical Sciences, Link&#xf6;ping University, Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strevens</LastName><ForeName>Helena</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Institute of Clinical Sciences, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>J&#xf6;nsen</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences Lund, Rheumatology, Lund University, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bengtsson</LastName><ForeName>Anders A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences Lund, Rheumatology, Lund University, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trysberg</LastName><ForeName>Estelle</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Rheumatology, Sahlgrenska University Hospital, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sennstr&#xf6;m</LastName><ForeName>Maria Majcuk</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Womens and Childrens Health, Division for Obstetrics and Gynecology, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zickert</LastName><ForeName>Agneta</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine Solna, Division of Rheumatology, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Svenungsson</LastName><ForeName>Elisabet</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medicine Solna, Division of Rheumatology, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gunnarsson</LastName><ForeName>Iva</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Medicine Solna, Division of Rheumatology, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christenson</LastName><ForeName>Karin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Oral Microbiology and Immunology, Institute of Odontology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bylund</LastName><ForeName>Johan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Oral Microbiology and Immunology, Institute of Odontology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacobsson</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Bioinformatics, Domain of Health Data and Digitalisation, Institute of Public Health, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rudin</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Guldhedsgatan 10A, Gothenburg, 405 30, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lundell</LastName><ForeName>Anna-Carin</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Guldhedsgatan 10A, Gothenburg, 405 30, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Arthritis Res Ther</MedlineTA><NlmUniqueID>101154438</NlmUniqueID><ISSNLinking>1478-6354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006098" MajorTopicYN="N">Granulocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007370" MajorTopicYN="Y">Interferon Type I</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autoantibody(ies)</Keyword><Keyword MajorTopicYN="N">Interferon alpha</Keyword><Keyword MajorTopicYN="N">Neutrophils</Keyword><Keyword MajorTopicYN="N">Pregnancy</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus (SLE)</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>23</Day><Hour>1</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>22</Day><Hour>23</Hour><Minute>38</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37349744</ArticleId><ArticleId IdType="pmc">PMC10286457</ArticleId><ArticleId IdType="doi">10.1186/s13075-023-03092-w</ArticleId><ArticleId IdType="pii">10.1186/s13075-023-03092-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tsokos GC. Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol. 2020;21(6):605&#x2013;614. doi: 10.1038/s41590-020-0677-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0677-6</ArticleId><ArticleId IdType="pmc">PMC8135909</ArticleId><ArticleId IdType="pubmed">32367037</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnado A, Hubbard J, Green S, Camai A, Wheless L, Osmundson S. Systemic lupus erythematosus delivery outcomes are unchanged across three decades. ACR Open Rheumatol. 2022;4(8):711&#x2013;720. doi: 10.1002/acr2.11447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr2.11447</ArticleId><ArticleId IdType="pmc">PMC9374054</ArticleId><ArticleId IdType="pubmed">35670028</ArticleId></ArticleIdList></Reference><Reference><Citation>Bundhun PK, Soogund MZ, Huang F. Impact of systemic lupus erythematosus on maternal and fetal outcomes following pregnancy: a meta-analysis of studies published between years 2001&#x2013;2016. J Autoimmun. 2017;79:17&#x2013;27. doi: 10.1016/j.jaut.2017.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2017.02.009</ArticleId><ArticleId IdType="pubmed">28256367</ArticleId></ArticleIdList></Reference><Reference><Citation>Buyon JP, Kim MY, Guerra MM, Laskin CA, Petri M, Lockshin MD, et al. Predictors of pregnancy outcomes in patients with lupus: a cohort study. Ann Intern Med. 2015;163(3):153&#x2013;163. doi: 10.7326/M14-2235.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M14-2235</ArticleId><ArticleId IdType="pmc">PMC5113288</ArticleId><ArticleId IdType="pubmed">26098843</ArticleId></ArticleIdList></Reference><Reference><Citation>Saleh M, Sj&#xf6;wall C, Strevens H, J&#xf6;nsen A, Bengtsson AA, Compagno M. Adverse pregnancy outcomes after multi-professional follow-up of women with systemic lupus erythematosus: an observational study from a single centre in Sweden. J Clin Med. 2020;9(8):2598. doi: 10.3390/jcm9082598.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9082598</ArticleId><ArticleId IdType="pmc">PMC7464390</ArticleId><ArticleId IdType="pubmed">32796552</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakobsen IM, Helmig RB, Stengaard-Pedersen K. Maternal and foetal outcomes in pregnant systemic lupus erythematosus patients: an incident cohort from a stable referral population followed during 1990&#x2013;2010. Scand J Rheumatol. 2015;44(5):377&#x2013;384. doi: 10.3109/03009742.2015.1013982.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/03009742.2015.1013982</ArticleId><ArticleId IdType="pubmed">26087812</ArticleId></ArticleIdList></Reference><Reference><Citation>Borella E, Lojacono A, Gatto M, Andreoli L, Taglietti M, Iaccarino L, et al. Predictors of maternal and fetal complications in SLE patients: a prospective study. Immunol Res. 2014;60(2&#x2013;3):170&#x2013;176. doi: 10.1007/s12026-014-8572-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-014-8572-6</ArticleId><ArticleId IdType="pubmed">25398639</ArticleId></ArticleIdList></Reference><Reference><Citation>Bremme K, Honkanen S, Gunnarsson I, Chaireti R. The presence of lupus nephritis additionally increases the risk of preeclampsia among pregnant women with systemic lupus erythematosus. Lupus. 2021;30(7):1031&#x2013;1038. doi: 10.1177/09612033211004716.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033211004716</ArticleId><ArticleId IdType="pmc">PMC8120629</ArticleId><ArticleId IdType="pubmed">33840282</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakravarty EF, Col&#xf3;n I, Langen ES, Nix DA, El-Sayed YY, Genovese MC, et al. Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. Am J Obstet Gynecol. 2005;192(6):1897&#x2013;1904. doi: 10.1016/j.ajog.2005.02.063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajog.2005.02.063</ArticleId><ArticleId IdType="pubmed">15970846</ArticleId></ArticleIdList></Reference><Reference><Citation>Cort&#xe9;s-Hern&#xe1;ndez J, Ordi-Ros J, Paredes F, Casellas M, Castillo F, Vilardell-Tarres M. Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. Rheumatology (Oxford) 2002;41(6):643&#x2013;650. doi: 10.1093/rheumatology/41.6.643.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/41.6.643</ArticleId><ArticleId IdType="pubmed">12048290</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirestam L, Arve S, Linge P, Bengtsson AA. Neutrophils-important communicators in systemic lupus erythematosus and antiphospholipid syndrome. Front Immunol. 2019;10:2734. doi: 10.3389/fimmu.2019.02734.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02734</ArticleId><ArticleId IdType="pmc">PMC6882868</ArticleId><ArticleId IdType="pubmed">31824510</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta AK, Joshi MB, Philippova M, Erne P, Hasler P, Hahn S, et al. Activated endothelial cells induce neutrophil extracellular traps and are susceptible to NETosis-mediated cell death. FEBS Lett. 2010;584(14):3193&#x2013;3197. doi: 10.1016/j.febslet.2010.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2010.06.006</ArticleId><ArticleId IdType="pubmed">20541553</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlucci PM, Purmalek MM, Dey AK, Temesgen-Oyelakin Y, Sakhardande S, Joshi AA, et al. Neutrophil subsets and their gene signature associate with vascular inflammation and coronary atherosclerosis in lupus. JCI Insight. 2018;3(8):e99276. doi: 10.1172/jci.insight.99276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.99276</ArticleId><ArticleId IdType="pmc">PMC5931124</ArticleId><ArticleId IdType="pubmed">29669944</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Banchereau R, Maslow BL, Guerra MM, Cardenas J, Baisch J, et al. Longitudinal profiling of human blood transcriptome in healthy and lupus pregnancy. J Exp Med. 2019;216(5):1154&#x2013;1169. doi: 10.1084/jem.20190185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20190185</ArticleId><ArticleId IdType="pmc">PMC6504211</ArticleId><ArticleId IdType="pubmed">30962246</ArticleId></ArticleIdList></Reference><Reference><Citation>Hacbarth E, Kajdacsy-Balla A. Low density neutrophils in patients with systemic lupus erythematosus, rheumatoid arthritis, and acute rheumatic fever. Arthritis Rheum. 1986;29(11):1334&#x2013;1342. doi: 10.1002/art.1780291105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780291105</ArticleId><ArticleId IdType="pubmed">2430586</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman S, Sagar D, Hanna RN, Lightfoot YL, Mistry P, Smith CK, et al. Low-density granulocytes activate T cells and demonstrate a non-suppressive role in systemic lupus erythematosus. Ann Rheum Dis. 2019;78(7):957&#x2013;966. doi: 10.1136/annrheumdis-2018-214620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214620</ArticleId><ArticleId IdType="pmc">PMC6585283</ArticleId><ArticleId IdType="pubmed">31040119</ArticleId></ArticleIdList></Reference><Reference><Citation>Villanueva E, Yalavarthi S, Berthier CC, Hodgin JB, Khandpur R, Lin AM, et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol. 2011;187(1):538&#x2013;552. doi: 10.4049/jimmunol.1100450.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1100450</ArticleId><ArticleId IdType="pmc">PMC3119769</ArticleId><ArticleId IdType="pubmed">21613614</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassani M, Hellebrekers P, Chen N, van Aalst C, Bongers S, Hietbrink F, et al. On the origin of low-density neutrophils. J Leukoc Biol. 2020;107(5):809&#x2013;818. doi: 10.1002/JLB.5HR0120-459R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JLB.5HR0120-459R</ArticleId><ArticleId IdType="pmc">PMC7318192</ArticleId><ArticleId IdType="pubmed">32170882</ArticleId></ArticleIdList></Reference><Reference><Citation>Stockfelt M, Larsson G, Engstr&#xf6;m H, Puttonen H, Zetterberg H, Blennow K, et al. Activated low-density granulocytes in peripheral and intervillous blood and neutrophil inflammation in placentas from SLE pregnancies. Lupus Sci Med. 2021;8(1):e000463. doi: 10.1136/lupus-2020-000463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2020-000463</ArticleId><ArticleId IdType="pmc">PMC7942245</ArticleId><ArticleId IdType="pubmed">33685997</ArticleId></ArticleIdList></Reference><Reference><Citation>Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003;100(5):2610&#x2013;2615. doi: 10.1073/pnas.0337679100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0337679100</ArticleId><ArticleId IdType="pmc">PMC151388</ArticleId><ArticleId IdType="pubmed">12604793</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodero MP, Decalf J, Bondet V, Hunt D, Rice GI, Werneke S, et al. Detection of interferon alpha protein reveals differential levels and cellular sources in disease. J Exp Med. 2017;214(5):1547&#x2013;1555. doi: 10.1084/jem.20161451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20161451</ArticleId><ArticleId IdType="pmc">PMC5413335</ArticleId><ArticleId IdType="pubmed">28420733</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;nnblom L, Leonard D. Interferon pathway in SLE: one key to unlocking the mystery of the disease. Lupus Sci Med. 2019;6(1):e000270. doi: 10.1136/lupus-2018-000270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2018-000270</ArticleId><ArticleId IdType="pmc">PMC6703304</ArticleId><ArticleId IdType="pubmed">31497305</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathian A, Mouries-Martin S, Dorgham K, Devilliers H, Barnabei L, Ben Salah E, et al. Monitoring disease activity in systemic lupus erythematosus with single-molecule array digital enzyme-linked immunosorbent assay quantification of serum interferon-alpha. Arthritis Rheumatol. 2019;71(5):756&#x2013;765. doi: 10.1002/art.40792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40792</ArticleId><ArticleId IdType="pubmed">30507062</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathian A, Mouries-Martin S, Dorgham K, Devilliers H, Yssel H, Garrido Castillo L, et al. Ultrasensitive serum interferon-alpha quantification during SLE remission identifies patients at risk for relapse. Ann Rheum Dis. 2019;78(12):1669&#x2013;1676. doi: 10.1136/annrheumdis-2019-215571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215571</ArticleId><ArticleId IdType="pubmed">31570366</ArticleId></ArticleIdList></Reference><Reference><Citation>Psarras A, Wittmann M, Vital EM. Emerging concepts of type I interferons in SLE pathogenesis and therapy. Nat Rev Rheumatol. 2022;18(10):575&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">36097207</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovgren T, Eloranta ML, Bave U, Alm GV, Ronnblom L. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 2004;50(6):1861&#x2013;1872. doi: 10.1002/art.20254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.20254</ArticleId><ArticleId IdType="pubmed">15188363</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovgren T, Eloranta ML, Kastner B, Wahren-Herlenius M, Alm GV, Ronnblom L. Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjogren&#x2019;s syndrome autoantigen-associated RNA. Arthritis Rheum. 2006;54(6):1917&#x2013;1927. doi: 10.1002/art.21893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.21893</ArticleId><ArticleId IdType="pubmed">16729300</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Romo GS, Caielli S, Vega B, Connolly J, Allantaz F, Xu Z, et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med. 2011;3(73):73ra20. doi: 10.1126/scitranslmed.3001201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3001201</ArticleId><ArticleId IdType="pmc">PMC3143837</ArticleId><ArticleId IdType="pubmed">21389264</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 2005;52(5):1491&#x2013;1503. doi: 10.1002/art.21031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.21031</ArticleId><ArticleId IdType="pubmed">15880830</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Linden M, van den Hoogen LL, Westerlaken GHA, Fritsch-Stork RDE, van Roon JAG, Radstake T, et al. Neutrophil extracellular trap release is associated with antinuclear antibodies in systemic lupus erythematosus and anti-phospholipid syndrome. Rheumatology (Oxford) 2018;57(7):1228&#x2013;1234. doi: 10.1093/rheumatology/key067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/key067</ArticleId><ArticleId IdType="pubmed">29608758</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Hoogen LL, Fritsch-Stork RD, van Roon JA, Radstake TR. Low-density granulocytes are increased in antiphospholipid syndrome and are associated with anti-&#x3b2;2 -glycoprotein I antibodies: comment on the article by Yalavarthi et al. Arthritis Rheumatol. 2016;68(5):1320&#x2013;1321.</Citation><ArticleIdList><ArticleId IdType="pubmed">26749538</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi: 10.1002/art.1780400928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Orbai AM, Alarc&#xf3;n GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677&#x2013;2686. doi: 10.1002/art.34473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473</ArticleId><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Iba&#xf1;ez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference><Reference><Citation>Denny MF, Yalavarthi S, Zhao W, Thacker SG, Anderson M, Sandy AR, et al. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J Immunol. 2010;184(6):3284&#x2013;3297. doi: 10.4049/jimmunol.0902199.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0902199</ArticleId><ArticleId IdType="pmc">PMC2929645</ArticleId><ArticleId IdType="pubmed">20164424</ArticleId></ArticleIdList></Reference><Reference><Citation>Lande R, Ganguly D, Facchinetti V, Frasca L, Conrad C, Gregorio J, et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med. 2011;3(73):73ra19. doi: 10.1126/scitranslmed.3001180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3001180</ArticleId><ArticleId IdType="pmc">PMC3399524</ArticleId><ArticleId IdType="pubmed">21389263</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Hoogen LL, van der Linden M, Meyaard L, Fritsch-Stork RDE, van Roon JA, Radstake TR. Neutrophil extracellular traps and low-density granulocytes are associated with the interferon signature in systemic lupus erythematosus, but not in antiphospholipid syndrome. Ann Rheum Dis. 2020;79(10):e135. doi: 10.1136/annrheumdis-2019-215781.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215781</ArticleId><ArticleId IdType="pubmed">31177097</ArticleId></ArticleIdList></Reference><Reference><Citation>Maria NI, Brkic Z, Waris M, van Helden-Meeuwsen CG, Heezen K, van de Merwe JP, et al. MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogren&#x2019;s syndrome. Ann Rheum Dis. 2014;73(6):1052&#x2013;1059. doi: 10.1136/annrheumdis-2012-202552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-202552</ArticleId><ArticleId IdType="pmc">PMC4033122</ArticleId><ArticleId IdType="pubmed">23831963</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacre K, Criswell LA, McCune JM. Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res Ther. 2012;14(3):R155. doi: 10.1186/ar3895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar3895</ArticleId><ArticleId IdType="pmc">PMC3446541</ArticleId><ArticleId IdType="pubmed">22734582</ArticleId></ArticleIdList></Reference><Reference><Citation>Oke V, Gunnarsson I, Dorschner J, Eketj&#xe4;ll S, Zickert A, Niewold TB, et al. High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. Arthritis Res Ther. 2019;21(1):107. doi: 10.1186/s13075-019-1878-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-019-1878-y</ArticleId><ArticleId IdType="pmc">PMC6489203</ArticleId><ArticleId IdType="pubmed">31036046</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiche L, Jourde-Chiche N, Whalen E, Presnell S, Gersuk V, Dang K, et al. Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. Arthritis Rheumatol. 2014;66(6):1583&#x2013;1595. doi: 10.1002/art.38628.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38628</ArticleId><ArticleId IdType="pmc">PMC4157826</ArticleId><ArticleId IdType="pubmed">24644022</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Sherbiny YM, Psarras A, Md Yusof MY, Hensor EMA, Tooze R, Doody G, et al. A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features. Sci Rep. 2018;8(1):5793. doi: 10.1038/s41598-018-24198-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-24198-1</ArticleId><ArticleId IdType="pmc">PMC5895784</ArticleId><ArticleId IdType="pubmed">29643425</ArticleId></ArticleIdList></Reference><Reference><Citation>Trutschel D, Bost P, Mariette X, Bondet V, Llibre A, Posseme C, et al. Variability of primary Sjogren&#x2019;s syndrome is driven by interferon-alpha and interferon-alpha blood levels are associated with the class II HLA-DQ locus. Arthritis Rheumatol. 2022;74(12):1991&#x2013;2002. doi: 10.1002/art.42265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42265</ArticleId><ArticleId IdType="pmc">PMC10092541</ArticleId><ArticleId IdType="pubmed">35726083</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladigau G, Haselmayer P, Scharrer I, Munder M, Prinz N, Lackner K, et al. A role for Toll-like receptor mediated signals in neutrophils in the pathogenesis of the anti-phospholipid syndrome. PLoS One. 2012;7(7):e42176. doi: 10.1371/journal.pone.0042176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0042176</ArticleId><ArticleId IdType="pmc">PMC3409186</ArticleId><ArticleId IdType="pubmed">22860075</ArticleId></ArticleIdList></Reference><Reference><Citation>Bashant KR, Aponte AM, Randazzo D, Rezvan Sangsari P, Wood AJ, Bibby JA, et al. Proteomic, biomechanical and functional analyses define neutrophil heterogeneity in systemic lupus erythematosus. Ann Rheum Dis. 2021;80(2):209&#x2013;218. doi: 10.1136/annrheumdis-2020-218338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218338</ArticleId><ArticleId IdType="pmc">PMC7855438</ArticleId><ArticleId IdType="pubmed">32988843</ArticleId></ArticleIdList></Reference><Reference><Citation>Marder W, Knight JS, Kaplan MJ, Somers EC, Zhang X, O&#x2019;Dell AA, et al. Placental histology and neutrophil extracellular traps in lupus and pre-eclampsia pregnancies. Lupus Sci Med. 2016;3(1):e000134. doi: 10.1136/lupus-2015-000134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2015-000134</ArticleId><ArticleId IdType="pmc">PMC4854113</ArticleId><ArticleId IdType="pubmed">27158525</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenna E, Mhaonaigh AU, Wubben R, Dwivedi A, Hurley T, Kelly LA, et al. Neutrophils: need for standardized nomenclature. Front Immunol. 2021;12:602963. doi: 10.3389/fimmu.2021.602963.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.602963</ArticleId><ArticleId IdType="pmc">PMC8081893</ArticleId><ArticleId IdType="pubmed">33936029</ArticleId></ArticleIdList></Reference><Reference><Citation>Blazkova J, Gupta S, Liu Y, Gaudilliere B, Ganio EA, Bolen CR, et al. Multicenter systems analysis of human blood reveals immature neutrophils in males and during pregnancy. J Immunol. 2017;198(6):2479&#x2013;2488. doi: 10.4049/jimmunol.1601855.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1601855</ArticleId><ArticleId IdType="pmc">PMC5337813</ArticleId><ArticleId IdType="pubmed">28179497</ArticleId></ArticleIdList></Reference><Reference><Citation>Belo L, Santos-Silva A, Rocha S, Caslake M, Cooney J, Pereira-Leite L, et al. Fluctuations in C-reactive protein concentration and neutrophil activation during normal human pregnancy. Eur J Obstet Gynecol Reprod Biol. 2005;123(1):46&#x2013;51. doi: 10.1016/j.ejogrb.2005.02.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejogrb.2005.02.022</ArticleId><ArticleId IdType="pubmed">16260340</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraus TA, Engel SM, Sperling RS, Kellerman L, Lo Y, Wallenstein S, et al. Characterizing the pregnancy immune phenotype: results of the viral immunity and pregnancy (VIP) study. J Clin Immunol. 2012;32(2):300&#x2013;311. doi: 10.1007/s10875-011-9627-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-011-9627-2</ArticleId><ArticleId IdType="pmc">PMC7086597</ArticleId><ArticleId IdType="pubmed">22198680</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraus TA, Sperling RS, Engel SM, Lo Y, Kellerman L, Singh T, et al. Peripheral blood cytokine profiling during pregnancy and post-partum periods. Am J Reprod Immunol. 2010;64(6):411&#x2013;426. doi: 10.1111/j.1600-0897.2010.00889.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0897.2010.00889.x</ArticleId><ArticleId IdType="pubmed">20712812</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>